Plasmodium falciparum antigens inducing protective antibodies

Details Plasmodium falciparum antigens inducing protective antibodies Plasmodium falciparum antigens inducing protective antibodies

2007-05-01

2007-05-01

Minifield, Nita (Department: 1645)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S151100, C424S142100, C424S139100, C514S002600, C530S387100, C530S391100, C530S388100, C530S389100, C530S387300, C530S387900, C530S388150, C530S388200, C530S388600

Reexamination Certificate

active

11142392

ABSTRACT:
The present invention relates, in part, to a purified polyclonal or monoclonal antibody which recognizes an epitope of a protein of 48,000 dalton, where the protein recognizes is a surface protein of a merozoite ofPlasmodium falciparumwhich has a peptide of SEQ ID NO:1 or a sequence wherein SEQ ID NO:1 has been modified by insertion, deletion or substitution and the sequence inhibits the binding of monoclonal antibody 245 toPlasmodiummerozoites, as well as fragments of the antibody; the present invention relates to composition and kits containing the same, as well as methods of using the same.

REFERENCES:
patent: 4632909 (1986-12-01), Carter et al.
patent: 4722840 (1988-02-01), Valenzucla et al.
patent: 4835259 (1989-05-01), Reese
patent: 4957738 (1990-09-01), Patarroyo
patent: 5032397 (1991-07-01), Duboise et al.
patent: 5112749 (1992-05-01), Brey et al.
patent: 5225534 (1993-07-01), Certa
patent: 5376370 (1994-12-01), Siddiqui
patent: 5585268 (1996-12-01), Knapp et al.
patent: 5589343 (1996-12-01), Marchand et al.
patent: 5599542 (1997-02-01), Marchand et al.
patent: 5602031 (1997-02-01), Marchand et al.
patent: 5720959 (1998-02-01), Holder et al.
patent: 6017538 (2000-01-01), Druilhe et al.
patent: 6191270 (2001-02-01), Druilhe et al.
patent: 6472519 (2002-10-01), Druilhe et al.
patent: 6949627 (2005-09-01), Druilhe et al.
patent: 7071296 (2006-07-01), Druilhe
patent: 7078043 (2006-07-01), Holder et al.
patent: 7078507 (2006-07-01), Narum et al.
patent: 2003/0161840 (2003-08-01), Druilhe
patent: 2004/0096466 (2004-05-01), Druilhe et al.
patent: 2004/0141987 (2004-07-01), Druilhe
patent: 2005/0112133 (2005-05-01), Druilhe
patent: 2005/0266017 (2005-12-01), Druilhe et al.
patent: 2006/0030006 (2006-02-01), Druilhe
patent: 2006/0188527 (2006-08-01), Hoffman et al.
patent: 2006/0216298 (2006-09-01), Druilhe
patent: 1526178 (2005-04-01), None
patent: 2378949 (2003-02-01), None
patent: WO 88/00595 (1988-01-01), None
patent: WO 90/02752 (1990-03-01), None
patent: WO 92/02549 (1992-02-01), None
patent: WO 2004/043488 (2004-05-01), None
patent: WO 2005/040206 (2005-05-01), None
Majarian et al, J. Immunology, Jun. 1984, 132/6:3131-3137.
Pleass et al, Blood, 2003, 102:4424-4430.
Sachdeva et al, Vaccine, 2006, 24:2007-2016.
Miller et al, Nature Medicine Vaccine Supplement, May 1998, 4/5:520-524.
Parasitology, vol. 95, pp. 229-240, 1987, J.L. Li and Y.J. Ki, “Inhibitory, Opsonic and Cytotoxic Activities of Homoclonal Antibodies Against Asexual Erythrocytic Stages of Plsmodium Falciparum.”
Infection and Immunity, vol. 60, No. 4, pp. 1473-1481, 1992, Hasnana Bouhroun-Tayoun, et al., “Plasmodium Falciparum Malaria: Evidence for an Isotype Imbalance which may be responsible for delayed acquisition of protective immunity.”
C.R. Acad. Scii., 1993, pp. 395-399, Claud Ceuvray, et al, “Characterization of a Plasmodium Falciparum Herozolte Surface Antigen Targeted by Defense Mechanisms Developed in Immune Individuals.”
Chappel, et al., Infection & Imjunity., 62/10: 448-4494, 1994.
Sherwood, et al., 1996, Vaccine, 14(8):817-827.
Romero, P.: Malaria Vaccines, Current Opin. Immunol. 4:432-441, 1992.
Butcher, 1989, Parasitol, 98:315-327.
Cox 1991, TIBTECH, 9:389-394.
Bowie, et al., 1990, Science, 247:1306-1310.
Houghten, et al., 1986, Vaccines 86, pp. 21-25.
Bixler, et al., 1987, In Synthetic Vaccines, vol. 1:39-71.
Oeuvray et al., Mem. Inst. Oswaldo Cruz, Riode Janeiro 89/11:77-80, 1984.
Khusmith et al., Bull. Soc. Path., E4, 76:137-145, 1983.
Barale, et al., Inf. 7 Imm. 65(8):3003-3010, Aug. 1997.
Khusmith, et al., Trans. Roy. Soc. Trop. Md. & Hyg. 76(3):423-424, 1982.
Khusmith, et al., Trans. Roy. Soc. Trop. Med. & Hyg. 76(3):423-424, 1982.
Fenton et al., 1991, Mol. & Cell. Biol. 11(2):963-71.
Snewin, et al., 1991, Mol. & Biomed. Parasitol, 49:265-276.
Saul. et al., 1992, J. Immunol, 148(1):208-211.
Taylor et al., 1995, Inf. & Imm. 63(11):4382-88.
Rutgers, et al., 1988, Bio/Technology, 6:1065-70.
Oeuvary, et al., 1994, Blood, 84(5):1594-1502.
Marshall, et al., 1991, Mol. & Biomed, Parasitol, 45:349-51.
McBride, et al., 1985, J. Exp. Med. 161:160-180.
Flint, et al., 1986, Vaccines 86, pp. 175-179, Ed. Brown et al.
Perkins, et al. 1986, Vaccines 86, pp. 157-160.
Von Brunn, et al., 1991, Vaccine 9:477-484.
Nester et al., 1996, Lancet, 348:701-707.
Snewin, et al. Mol. & Biochem. Parasitol, 49:265-275, 1991.
Khusmith, et al. Trans. Royal Soc. Trop. Med. & Hyg. 76/3:423-424, 1982.
Druilhe et al., Infection & Immunity, 55/4:888-891, 1987.
Oeuvray, et al., Blood, 84:1594-1602, 1994.
Yang, et al., Vaccine, 15/12-13:1303-1313, 1997.
Dong et al., Int. J. Parasitology; 31:57-62, 2001.
Sauzet, et al. Infection & Immunity, 69:2:1202-1206, 2001.
DaSilveira et al., Infection & Immunity, 67/11:5906-5916, 1999.
Rzepczyk, et al., Infection & Immunity, 65/3:1098-1100, 1997.
Oeuvray, et al., Infection & Immunity, 68/5:2617-2620, 2000.
Huber, et al., Mol. Biochem. Parasitol, 87:231-234.
Okenu, et al., Mol.Biochem. Pavasitol, 109:185-188, 2000.
McCall et al., Mol. iochem. Parasitol, 90:21-31, 1997.
Benjamin, et al., Mol. Iochem. Parasitol, 104/147-156, 1999.
Ramasamy, et al., BBA, 1453:1-13, 1999.
Fenton, et al., Mol. & Cellular Biol., 11/2:963-971, 1991.
Benzaquen-Geffin, et al., Infection & Immunity, 55/2:342-51, 1987.
Pye, et al., Infection & Immunity, 59/7:2403-02411, 1991.
Fenton, et al., Mol & Biochem. Parasutology, 34:79-86, 1989.
Holder, et al., Parasitology, 97:373-382, 1988.
Bums, et al., J. Immunology, 143:2670-2676, 1989.
Cheung, et al., PNAS, 83:8328-8332, 1986.
Druilhe et al., Inf. & Imm. 55(4):888-891, Apr. 1987.
Smythe, et al. PNAS, 88:1751-1755, 1991.
Gardner et al., Nature, 2002, 419-498-511.
Hirunpetcharat, et al. J. Immunology, 1999, 162:7309-7314.
Morales-Betoulle, et al. Experimental Parasitology, 1998, 90:49-57.
Spencer Valero, et al. Infection and Immunity. Aug. 1998, 66/8:3925-3930.
Ak, et al. Infection and Immunity, Jun. 1993, 61/6:2493-2497.
Badell, et al. J. Exp. Med., Dec. 4, 2000, 192/11:1653-1659.
Narum, et al. Infection and immunity, May 2000, 68/5:2899-2906.
Elawad, et al. Tropical Medicine and International Health, Dec. 1999, 4/12:812-813.
Benjamin, et al. Molecular and biochemical Parasitology, 1999, 104:147-156.
White, et al. Infection and Immunity, Oct. 1991, 59/10:3547-3554.
Kawabata, et al, Infection and Immunity, Nov. 2002, 70/11:6075-6082.
Vukovic, et al. Vaccine, 2002, 20:2826-2835.
Yoneto, et al., J. Immunology, 2001, 166:6236-6241.
Sina, et al., Molecular and Biochemical Parasitology, 1995.
Reed et al., Vaccine, 1997, 15/5:482-488.
Rowe et al., Vaccine, 2004, 22:3986-3992.
Bouharoun-Tayoun, et al., Experimental Parasitology, 2004, 108:47-52.
Sabchareon, et al., Am. J. Troop. Med. Hyg., 1991-45/3:297-308.
Rollinghoff, et al., Encyclopedia of Life Sciences, 2001, pp. 1-7.
Singh, et al., Microbes and Infection, 2000, 2:473-480.
Claude Oeuvray, et al., “Merozoite Surface Protein-3: A Malaria Protein Inducing Antibodies That Promote Plasmodium falciparum Killing by Cooperation with Blood Monocytes,” Blood, vol. 84, No. 5, Sep. 1, 1994, pp. 1594-1602.
Edgar Badell, et al., “Human Malaria in Immunocompromised Mice: An In Vivo Model to Study Defense Mechanisms against Plasmodium falciparum,” J. Exp. Med., vol. 192, No. 11, Dec. 4, 2000, pp. 1653-1659.
Subhash Singh, et al., “Identification of a Conserved Region of Plasmodium falciparum MSP3 Targeted by Biologically Active Antibodies to Improve Vaccine Design,” JID, Sep. 1, 2004, pp. 1010-1018.
Pierre Druilhe, et al., “A Malaria Vaccine that Elicits in Humans Antibodies Able to Kill Plasmodium falciparum,” PLoS Medicine, vol. 2, Issue 11, Nov. 2005, pp. 1135-1147.

Affiliated with

Also associated with

Rating

Plasmodium falciparum antigens inducing protective antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Plasmodium falciparum antigens inducing protective antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasmodium falciparum antigens inducing protective antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3748632